IP Library › Granted Patent US 8,877,743
Granted Patent B2
US 8,877,743 · App. 13/917,932 · Granted Nov 4, 2014

Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors

Inventors: Samarendra N. Maiti (Edmonton, CA); Dai Nguyen (Edmonton, CA); Jehangir Khan (Edmonton, CA); Rong Ling (Edmonton, CA)
Assignee: Naeja Pharmaceutical Inc.
A61K31/46C07D519/00A61K31/55A61K31/4985A61K31/541A61K31/496A61K31/439C07D471/08A61K31/553A61K45/06A61K31/5377C07D451/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,877,743
App. No.
13/917,932
Granted
Nov 4, 2014
Kind
B2
Abstract

A compound of formula (I): wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; and R 1 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.

Claims (33)

1. A compound of formula (I):

wherein:

M is hydrogen or a pharmaceutically acceptable salt-forming cation;

R 1 is a radical selected from the group consisting of:

(1) C 1-6 straight or branched chain alkyl which is optionally substituted; and

(2) C 3-7 cycloalkyl which is optionally substituted;

or a deuterated compound of any such compound.

2. A compound as recited in claim 1 , wherein R 1 is optionally substituted with one or two substituents independently selected from the following: lower alkyl, amino, substituted amino, amidino, and guanidino.

3. A compound as recited in claim 1 , which is selected from the following group of compounds:

and pharmaceutically acceptable salts of such compounds, and deuterated compounds of such compounds and salts.

4. A compound of formula (I) as defined in claim 1 , wherein the compound is selected from the group consisting of:

(2S,5R)—N-(2-aminoethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)—N-[(2-aminocyclopropyl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)—N-[(2-(methylamino)ethoxy]-7-oxo-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)—N-(3-aminopropoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)—N-[3-(methylamino)propoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)—N-[(2S)-2-aminopropoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)—N-[(2R)-2-aminopropoxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)—N-[(2-aminocyclobutyl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

(2S,5R)—N-[(2-aminocyclopentyl)oxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

or a deuterated compound of any such compound.

5. A pharmaceutical composition containing as an active ingredient, at least one compound as recited in claim 1 .

6. A molecular complex comprising a compound as recited claim 1 and at least one solvent.

7. A molecular complex as recited in claim 6 , wherein the solvent comprises water.

8. A compound of the following formula:

and pharmaceutically acceptable salts thereof, and deuterated compounds thereof and salts.

9. (2S,5R)—N-(2-aminoethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide or a deuterated compound thereof.

10. A pharmaceutical composition containing as an active ingredient, the compound of claim 8 .

11. A pharmaceutical composition containing as an active ingredient, the compound of claim 9 .

12. A molecular complex comprising the compound of claim 8 and at least one solvent.

13. The molecular complex as recited in claim 12 , wherein the solvent comprises water.

14. A molecular complex comprising the compound of claim 9 and at least one solvent.

15. The molecular complex as recited in claim 14 , wherein the solvent comprises water.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2015
From: NAEJA PHARMACEUTICAL INC.
To: FEDORA PHARMACEUTICALS INC.
Reel/Frame 034823/0783 →
Continuity (4)
Continuation 13690398 · Nov 30, 2012
Provisional Application 61566240 · Dec 2, 2011
Provisional Application 61641087 · May 1, 2012
Related Publication 20130281359A1 · Oct 24, 2013